|
Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients. |
|
|
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BIND Therapeutics; Blue Earth Diagnostics; Bristol-Myers Squibb; Chugai Pharma; Endocyte; Ferring; Genentech; Janssen; Med IQ; Medivation; OncologySTAT; Palmetto GBA; Pfizer; Sanofi; Takeda; Ventana Medical Systems; WIRB-Copernicus Group |
|
Research Funding - BIND Biosciences (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen (Inst); Janssen Diagnostics (Inst); Medivation (Inst) |
Travel, Accommodations, Expenses - Astellas Pharma; AstraZeneca; BIND Therapeutics; Bristol-Myers Squibb; Celgene; Endocyte; Ferring; Genentech; Janssen; Medivation; Pfizer; Sanofi; Takeda; WIRB-Copernicus Group |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
Travel, Accommodations, Expenses - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
|
Stock and Other Ownership Interests - Eisai |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
|
Stock and Other Ownership Interests - Eisai |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
|
|
Employment - Epic Sciences |
Leadership - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
Patents, Royalties, Other Intellectual Property - Epic Sciences |
Travel, Accommodations, Expenses - Epic Sciences |
|
|
No Relationships to Disclose |
|
|
Employment - Epic Sciences |
Leadership - Epic Sciences |
Stock and Other Ownership Interests - Epic Sciences |
Patents, Royalties, Other Intellectual Property - Patents Pending |